TNF and rheumatoid arthritis: Persistence in the anti-TNF therapy (+/-DMARD) in the first year of follow-up was 66.0% and 80.0% for the patients with RA and AS, respectively; in turn, these rates were reduced to 41.0% and 60.0% at the end of two years of follow-up.